Compare Amylx Pharmaceuticals Inc (AMLX) vs Amazon.com Inc (AMZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Amazon.com Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.86 (market cap $2.64B), while Amazon.com Inc trades at $269.13 (market cap $2.94T). The key difference: Amazon.com Inc is far larger — about 1113.6× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Amazon.com Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | AMZN | |
|---|---|---|
Market Cap | $2.64B | $2.94T |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $284.02 |
52-Week Low | $7.82 | $198.79 |
Enterprise Value | $2.39B | $3.04T |
Volume | — | 3,931,282 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Amazon (AMZN) trades at $267.84, down 3.69% over 24 hours, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including a 17.44% net income margin and robust revenue growth to $716.92 billion in 2025. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS and AI chip expansion, fueling investor confidence.
Outlook remains positive with a consensus price target of $333.86, indicating 25% upside potential. Risks include intense competition in e-commerce and cloud services, alongside high capital expenditures. Wall Street sentiment is overwhelmingly bullish, with 89% of analysts rating it a buy, though volatility from macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →
